SPRING-2 the future of antiretroviral therapy.
The Kirby Institute for infection and immunity in society, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
Mark A
MA
Boyd
David A
DA
Cooper
D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000302:isolation & purification*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir
D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir